Antiglaucoma medication and clinical depression
Antiglaucoma medication and clinical depression
复制标题
DOI：
10.1080/0004867010060503
复制
发表时间：
2001-10-01
影响因子：
4.6
通讯作者：
Tuckwell, V
中科院分区：
文献类型：
--
作者：
Schweitzer, I;Maguire, K;Tuckwell, V
目的：本文的目的是提醒医学界使用抗青光眼药物后出现临床抑郁症的潜在风险。方法：回顾了有关局部抗青光眼药物的全身副作用以及这些药物与临床抑郁症之间关系的现有文献。此外，据报道，有两例患者在使用局部倍他洛尔后出现临床抑郁症，但在更换青光眼药物后才完全缓解。 结果/结论：本文提供的病例报告增加了越来越多的将局部眼科 P-肾上腺素受体拮抗剂与抑郁症联系起来的文献。虽然这些病例并不常见，但医学界、精神科医生、眼科医生和全科医生仍然对这种现象认识不足。
Objective: The aim of this paper is to alert the medical community to the potential risk of clinical depression following the use of antiglaucoma medication.Method: The available literature concerning systemic side-effects of topical antiglaucoma medication and the association of these agents with clinical depression were reviewed. In addition, two cases are reported of the occurrence of clinical depression following use of topical betaxolol which only resolved completely after switching glaucoma medication.Results/Conclusions: The case reports presented here add to the increasing body of literature linking topical ophthalmic P-adrenoceptor antagonists with depression. While these cases are uncommon, this phenomenon continues to be poorly recognized by the medical profession, psychiatrists, ophthalmologists and general practitioners alike.